Theravance Biopharma

TBPH

Market cap $1.03B

DUBLIN , Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

DUBLIN , Nov. 19, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate in the following investor conferences in December 2025: 8th Annual Evercore Healthcare Conference Location: Coral Gables, FL Format: Fireside ChatDate: Thursday, December 4, 2025 Time: 8:20-8:40 AM ET Webcast Oppenheimer Movers in Rare Disease Summit Location: New York, NY Format: Panel Discussion - Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving CatalystsDate: Thursday, December 11, 2025 Time: 2:15-2:45 PM ET Theravance will be available for one-on-one meetings during both events. Interested investors should contact their respective representatives to request meetings.

Yupelri's strength helped Theravance achieve non-GAAP profitability this quarter. The company is on track for lucrative milestones.

TBPH delivers a third-quarter profit, beating estimates, and 19% revenue growth, fueled by rising collaboration income from Viatris related to Yupelri sales.

Theravance Biopharma, Inc. ( TBPH ) Q3 2025 Earnings Call November 10, 2025 5:00 PM EST Company Participants Rick Winningham - CEO & Director Rhonda Farnum - Chief Business Officer and Senior VP of Commercial & Medical Affairs Aine Miller - Senior VP of Development & Head of Ireland Office Aziz Sawaf - Senior VP & CFO Conference Call Participants Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Julian Harrison - BTIG, LLC, Research Division Ellen Horste - TD Cowen, Research Division Presentation Operator Ladies and gentlemen, good afternoon.

Theravance Biopharma (TBPH) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to a loss of $0.06 per share a year ago.

YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year 1 , and achieved record brand profitability Open-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine now complete; topline readout on track for Q1 2026 Company to host an ampreloxetine focused virtual Key Opinion Leader (KOL) event for investors on December 8, 2025 TRELEGY year-to-date sales on track to achieve $50 million milestone in 2025 2 Strong balance sheet with $333 million in cash and no debt DUBLIN , Nov. 10, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2025. "Theravance delivered strong results in the third quarter, highlighted by record YUPELRI net sales and the achievement of non-GAAP breakeven, underscoring our commitment to financial and operational discipline," said Rick E Winningham, Chief Executive Officer of Theravance Biopharma.

CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.

Ampreloxetine clinical development program to be featured in four presentations at the upcoming International Symposium on The Autonomic Nervous System Topline results from the ongoing Phase 3 CYPRESS study of ampreloxetine anticipated in Q1 2026 DUBLIN , Oct. 29, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will be participating at the 36th International Symposium on the Autonomic Nervous System, organized by the American Autonomic Society (AAS), taking place November 5-8, 2025, in Clearwater Beach, FL. The Company will have one platform presentation and three poster presentations on its clinical development program for ampreloxetine, a potential first-in-class norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) symptoms due to multiple system atrophy (MSA).